Skip to content

Arrowhead Pharmaceuticals

US · ARWR #1569 by market cap Listed 1970
41.37 -2.28 -5.22%
Periodic snapshot; not a real-time feed. · 2026-11-20 19:30

✦ Quant Financial Health how this is computed

Weak
  • Altman Z-Score is -0.22, below the 1.8 "distress zone" threshold.
  • Most reliable for industrial/manufacturing companies; less meaningful for banks, insurers and other financials.

Revenue annual, last 8 years

Latest year -45.65% YoY

Margins

Gross margin
99.60%
Operating margin
-156.86%
Net margin
-160.64%

Key ratios & quality

Altman Z-Score below ~1.8 suggests financial distress risk, above ~3.0 suggests low risk; the model is most reliable for industrial/manufacturing companies and less meaningful for banks and other financial firms.

Income statement

Line item 2019 2020 2021 2022 2023 2024 2025 2026
Revenue 168.80M87.99M138.29M243.23M240.74M3.55M829.45M450.82M
Gross profit ----------3.55M829.45M449.02M
Selling & admin expenses 26.56M52.28M80.98M124.43M90.93M96.82M121.92M200.14M
Research & development 81.05M128.88M206.34M297.31M353.19M505.87M607.16M954.14M
Operating profit 61.19M-93.16M-149.04M-178.51M-205.00M-601.08M98.35M-707.17M
Pretax profit 68.15M-84.55M-140.85M-172.71M-206.49M-612.46M51.53M-723.92M
Tax 174.00K2.00K2.00K3.79M2.78M-2.77M21.42M-6.78M
Net profit 67.98M-84.55M-140.85M-176.49M-209.28M-609.69M30.11M-717.13M
Basic EPS 1-1-1-2-2-50-5
Diluted EPS 0.69-0.84-1.36-1.67-1.92-5.00-0.01-5.11

Balance sheet

Line item 2019 2020 2021 2022 2023 2024 2025 2026
Total current assets 265.25M322.37M384.60M405.30M416.47M695.47M950.64M1.29B
Cash & ST investments 258.70M315.49M367.79M376.40M403.63M680.96M919.37M1.19B
Inventory ------------09.08M
Total assets 349.85M522.50M710.15M691.94M765.55M1.14B1.39B1.74B
Total current liabilities 97.07M40.68M146.54M138.85M105.46M103.17M195.49M311.34M
Short-term debt --1.10M2.25M2.78M10.56M6.34M47.29M45.50M
Long-term debt ----------393.18M214.88M838.88M
Total liabilities 105,809,185.0060,725,000.00301,326,000.00273,600,000.00478,390,000.00948,739,000.00881,879,000.001,687,753,000.00
Total equity 244.04M461.78M408.82M418.34M287.16M191.06M503.42M50.50M
Retained earnings -419.29M-503.84M-644.69M-820.76M-1.03B-1.63B-1.63B-2.35B

Cash flow

Line item 2019 2020 2021 2022 2023 2024 2025 2026
Operating cash flow 173.04M-95.80M171.31M-136.13M-153.89M-462.85M179.55M-271.95M
Depreciation & amortization 4.44M5.94M8.27M10.42M12.49M18.60M23.93M26.62M
Free cash flow 161.03M-107.75M147.75M-188.91M-330.63M-604.32M156.89M-283.94M
Dividends paid ----------------
Stock buybacks / issuance 60.52M250.48M--00450.02M241.39M206.11M
Ending cash balance 221.80M143.58M184.43M108.01M110.89M102.69M226.55M62.74M

Returns & efficiency

Line item 2019 2020 2021 2022 2023 2024 2025 2026
ROE % 39.94-23.94-32.36-43.62-61.29-262.48-0.50-280.50
ROA % 29.46-19.39-22.85-25.11-28.17-62.93-0.13-46.37
ROIC % 39.94-22.59-30.71-38.51-46.86-108.994.86-73.16
5-year avg ROE % -41.25-32.75-23.33-24.28-24.25-84.74-80.05-129.68
EBIT margin % 36.25-105.87-107.77-73.39-78.16-16,336.4716.99-139.79
FCF / sales % 95.40--106.78------18.91--
Current ratio 2.737.922.622.923.956.744.864.14
Quick ratio 2.677.782.582.723.836.604.743.86
Debt / assets 0.004.053.6011.7915.0444.7926.4457.54
LT debt / equity --4.345.7019.7738.55271.8968.451,897.52
Interest coverage ---------10.27-17.931.58-6.73
Revenue CAGR (3Y) % 921.5640.97104.6212.9539.86-70.5050.5223.26
Net income CAGR (3Y) % ----------------
FCF CAGR (3Y) % ----------------

Revenue breakdown most recent period

Business

Discovery, development, manufacturing and commercialization of RNA interference (RNAi) therapeutics100.00%

Quote time 2026-11-20 19:30:06 · For reference only, not investment advice and not tailored to your situation.

Arrowhead Pharmaceuticals discussion 0 comments

Add a comment